Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

1330362

	registered interest
	date	07/06/2021
	answering body	Treasury
	answering dept id	14
	answering dept short name	Treasury
	answering dept sort name	Treasury
	hansard heading	Cryptocurrencies: Environment Protection
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the level of energy use in the mining of Bitcoin, as identified by the Cambridge Bitcoin Electricity Consumption Index; and what steps they will take to address the environmental harms of cryptocurrencies.
	tabling member printed	Lord Mendelsohn
	uin	HL789
	answer	answer is ministerial correction date of answer 16/06/2021 answer text The Government has been monitoring developments within the cryptoasset industry, including rising energy usage.<p> </p><p>The Cryptoasset Taskforce, comprising HM Treasury, the Financial Conduct Authority, and the Bank of England, considers the impact of cryptoassets and assesses what, if any, regulation is required in response. The Government stands ready to respond to emerging risks or changes in the market and will continue to monitor developments in cryptoassets.</p><p> </p><p>In November 2020, the Chancellor announced that the UK will implement a green taxonomy – a common framework for determining which activities can be defined as environmentally sustainable – which will improve understanding of the impact of firms’ activities and investments on the environment and support our transition to a sustainable economy. More details on the green taxonomy will be announced in due course.</p>The Government has already taken action to ensure the UK is the world-leading centre for green finance including through announcing an intention to make disclosures aligned with the Taskforce on Climate-related Financial Disclosures (TCFD) fully mandatory across the economy by 2025, making the UK the first country to do so. answering member printed Lord Agnew of Oulton grouped question UIN HL787 HL788 question first answered 16/06/2021 10:45:08 answering member 4689 label Biography information for Lord Agnew of Oulton
	tabling member	4286 label Biography information for Lord Mendelsohn

1385194

	registered interest
	date	06/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Immunotherapy: Shortages
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what communications have been issued by the NHS in England about the immunoglobulin shortage to patient groups supporting people with immunodeficiency; and whether the NHS in England has communicated directly with patients to explain the situation and how it will affect them.
	tabling member printed	Lord Mendelsohn
	uin	HL4726
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>With the input of clinicians, professional bodies and patient groups, NHS England and NHS Improvement and the UK Primary Immunodeficiency Network have developed a patient information leaflet which was issued to National Health Service trusts on 8 November 2021, with a request to discuss and share with patients as part of individual clinical conversations. NHS England and NHS Improvement have also shared the leaflet with patient groups to circulate to affected members.</p><p>The patient information leaflet highlights that, due to the COVID-19 pandemic, fewer people have been able to donate blood, which has impacted the availability of immunoglobulin products both globally and in the United Kingdom. The patient information leaflet also explains what the impact of the global shortage of immunoglobulin products may mean for UK patients and how they can access support. A copy of the patient leaflet, <em>Immunoglobulin replacement therapy: Information for patients from the NHS and the UK Primary Immunodeficiency Network</em> is attached.</p> answering member printed Lord Kamall question first answered 20/12/2021 13:19:29 answering member 4909 label Biography information for Lord Kamall attachment 1 file name B0910_ii_Immunoglobulin - patient information leaflet_041121.docx title Immunoglobulin replacement therapy: Information fo
	tabling member	4286 label Biography information for Lord Mendelsohn

1437285

	registered interest
	date	01/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans, if any, they have to work with charities that represent clinically extremely vulnerable people to ensure that these groups rapidly receive communications concerning their risk from COVID-19 as restrictions and mandatory isolation comes to an end on 1 April.
	tabling member printed	Lord Mendelsohn
	uin	HL6546
	answer	answer is ministerial correction date of answer 15/03/2022 answer text <p>We will continue to meet with charities and stakeholders representing those whose immune system means they are at higher risk of serious illness from COVID-19. The Chief Executive of the UK Health Security Agency, Dr Jenny Harries, is the clinical lead for the programmes supporting these patients and has met with charities at stakeholder engagement sessions.</p> answering member printed Lord Kamall question first answered 15/03/2022 12:07:32 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1462730

	registered interest
	date	12/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why they have not recognised the laboratory assay tests conducted in (1) the US, and (2) the EU, on Evusheld against Omicron subvariants.
	tabling member printed	Lord Mendelsohn
	uin	HL215
	answer	answer is ministerial correction date of answer 25/05/2022 answer text <p>We understand that the United States of America has increased the suggested dose of Evusheld, in line with in vitro results showing that Evusheld has reduced efficacy against some Omicron subvariants. The Food and Drug Administration’s in vitro data was pseudovirus data, whereas the tests being conducted by the UK Health Security Agency (UKHSA) are based on live virus data. The European Medicines Agency has acknowledged the possibility that Evusheld has reduced efficacy against Omicron subvariants, based on laboratory studies. The data generated by the UKHSA will enhance our understanding of the effectiveness of Evusheld's neutralisation of Omicron subvariants, including BA.2.</p> answering member printed Lord Kamall question first answered 25/05/2022 11:30:45 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464287

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 27 April (HL7561), what conclusions they have reached following meetings with groups representing the immunocompromised community on how they can be involved in (1) creating, and (2) disseminating, (a) communication, and (b) guidance, to people about how to safely manage their ongoing risk.
	tabling member printed	Lord Mendelsohn
	uin	HL347
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL348 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464288

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to (1) communicate, and (2) consult, with (a) charities, and (b) patient organisations, as part of the COVID-19 enhanced protection programme (EPP); and what format this will take.
	tabling member printed	Lord Mendelsohn
	uin	HL348
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464289

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government who is responsible for leading the COVID-19 enhanced protection programme (EPP); and what is the process for (1) charities, and (2) patient organisations, to be designated as stakeholders for the programme.
	tabling member printed	Lord Mendelsohn
	uin	HL349
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL348 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1441625

	registered interest
	date	15/03/2022
	answering body	Department for Levelling Up, Housing and Communities
	answering dept id	211
	answering dept short name	Levelling Up, Housing and Communities
	answering dept sort name	Levelling Up, Housing and Communities
	hansard heading	Landlord and Tenant Act 1954
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government when they intend to undertake the review of the Landlord and Tenant Act 1954, announced in December 2021; and why that review has been delayed.
	tabling member printed	Lord Mendelsohn
	uin	HL6979
	answer	answer is ministerial correction date of answer 29/03/2022 answer text <p>We know there is concern that the Landlord and Tenant Act 1954, part II, has not kept pace with today’s commercial property sector. <br> <br> Government announced <a href="https://www.gov.uk/government/news/business-evictions-ban-extended-until-march" target="_blank">a review of the landlord and tenant legislation</a>  in December 2020. The review will develop proposals for a framework that helps support the efficient, flexible use of space and supports high streets and town centres. <br> <br> Over the last year, Government has prioritised developing an <a href="https://www.gov.uk/government/news/new-laws-and-code-to-resolve-remaining-covid-19-commercial-rent-debts" target="_blank">exit strategy from the moratorium on commercial evictions</a> , and resolution of pandemic-related rent debt via the Commercial Rent (Coronavirus) Act, which received Royal Assent on 24 March. Government recommitted to the review as part of the <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005041/Build_Back_Better_High_Streets.pdf" target="_blank">Build Back Better High Streets</a> strategy in July 2021, and officials are currently engaging across the sector to inform the scope and focus of the review; further details will be announced in due course.</p> answering member printed Lord Greenhalgh attachment 1 file name HL6979 Exit strategy from the moratorium on commercial evictions.docx title Exit strategy from the moratorium on commercial ev 2 file name HL 6979 Build Back Better High Streets.pdf title Build Back Better High Streets 3 file name HL 6979 Review of the landlord and tenant legislation.docx title Review of the landlord and tenant legislation question first answered 29/03/2022 16:57:24 answering member 4877 label Biography information for Lord Greenhalgh
	tabling member	4286 label Biography information for Lord Mendelsohn

1379168

	registered interest
	date	16/11/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to evaluate AZD7442 for emergency use as a preventative treatment against COVID-19; and what are the timelines for its approval.
	tabling member printed	Lord Mendelsohn
	uin	HL4096
	answer	answer is ministerial correction date of answer 01/12/2021 answer text <p>We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442. AstraZeneca are discussing potential approval for the therapy with the Medicines and Healthcare products Regulatory Agency.</p><p>We anticipate that further neutralising monoclonal antibody treatments will be submitted for evaluation for a marketing authorisation by the MHRA in the next few months. These treatments could become available for community treatment or preventative use.</p> answering member printed Lord Kamall question first answered 01/12/2021 12:02:25 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1358407

	registered interest
	date	04/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Ronapreve
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the (1) existing stock levels, (2) planned order quantities, and (3) delivery dates, for the COVID-19 antibody drug Ronapreve; and what is the (a) current, and (b) planned, geographic distribution of Ronapreve across England.
	tabling member printed	Lord Mendelsohn
	uin	HL2858
	answer	answer is ministerial correction date of answer 21/10/2021 answer text <p>We are unable to provide the information requested on existing stock levels, planned order quantities and delivery of Ronapreve, as this is commercially sensitive. A contract is in place for stock held in the United Kingdom which is available to order across the four nations. However, information on the distribution of this stock is not held centrally. Hospitals are able to replenish their supplies of Ronapreve according to their admission rates, with the majority of hospitals in England providing acute care now registered to administer the drug.</p> answering member printed Lord Kamall question first answered 21/10/2021 11:26:21 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn